CMRX Projected Dividend Yield
Chimerix Inc. ( NASDAQ : CMRX )Chimerix is a biopharmaceutical company focused on developing medicines that improve and extend the lives of patients facing deadly diseases. The U.S. Food and Drug Administration (FDA) approved TEMBEXA (brincidofovir) for the treatment of smallpox as a medical countermeasure. Co.'s two clinical-stage development programs are ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma as its lead indication. DSTAT is in Phase 3 development as a potential first-line therapy in combination with standard chemotherapy for the treatment of acute myeloid leukemia. 20 YEAR PERFORMANCE RESULTS |
CMRX Dividend History Detail CMRX Dividend News CMRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |